Target intelligence / Profile preview

E3 ubiquitin-protein ligase RNF212B (RNF212B)

Target
RNF212B
Molecular classification
Ubiquitin E3 ligase, RING finger protein, Enzyme
01

Overview

E3 ubiquitin-protein ligase RNF212B is a RING finger domain-containing enzyme essential for crossover designation and maturation during meiosis I in mammals[1][2][3]. RNF212B acts as a ubiquitin E3 ligase, collaborating with paralogs such as RNF212 to ensure accurate formation of crossovers and proper segregation of homologous chromosomes. Its loss leads to defects in meiosis, primarily causing loss of crossovers and aberrant chromosome segregation, which can result in infertility[1][2]. RNF212B forms foci on chromosome axes in a synapsis-dependent but double-strand break (DSB)-independent manner, and colocalizes with major recombination factors such as HEI10, CNTD1, and MLH1[1][2]. Although not currently established as a therapeutic target or druggable target in disease, pathogenic variants have been implicated in reproductive disorders in both mice and humans[1]. There are no reports of drugs targeting RNF212B, nor is it currently regarded as a therapeutic target in clinical development. It is primarily classified as a meiosis-essential enzyme, with its main relevance to fertility, rather than to cancer, infection, or other major common diseases[1][2][3].

Other names
C14orf164RING finger protein 212BRING finger protein C14orf164-like
02

Biological functions

Crossover (CO) formation during meiosisChiasma assemblyProtein ubiquitinationRegulation of meiotic recombination
03

Disease associations

Infertility/reproductive disorders (at least in animal models and a reported human variant)Fanconi anemia, complementation group F (genetic association reported)

Beyond the preview

Go deeper on E3 ubiquitin-protein ligase RNF212B (RNF212B).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on E3 ubiquitin-protein ligase RNF212B (RNF212B).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call